Loading clinical trials...

Ghrelin Levels in Pancreatic Cancer Patients | Clinical Trials | Clareo Health

COMPLETED

Ghrelin Levels in Pancreatic Cancer Patients

Assessment of Plasma Ghrelin Levels in Patients With Pancreatic Cancer

NCT00225745•Dartmouth-Hitchcock Medical Center

View on ClinicalTrials.gov

Summary

The primary outcome measure for this study is plasma ghrelin level.

Detailed Description

The primary outcome measure for this study is plasma ghrelin level, and the two primary comparison are: * Patients with cachexia versus patients without cachexia * Patients with cachexia versus healthy controls

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Histological or cytological proof of pancreatic adenocarcinoma
•The control are will include healthy age-matched patients without cancer
•The test arm will include patients with pancreatic cancer and they will divided into two groups: those with and without weight loss
•Patients must have recovered from any major infections and/or surgical procedures

Exclusion Criteria

•Patients with other serious medical illness like congestive heart failure, thyroid disease,liver disease or renal failure - conditions that will alter their nutritional state
•Patients on appetite stimulant and those receiving total parenteral nutrition
•Patients who have undergone gastrectomy or those who have gastric ulcers
•Patients receiving active chemotherapy
•No prior malignancy except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer or for which patient has been disease free for at least five years.

Locations (1)

Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center

Lebanon, New Hampshire, United States

Key Dates

Start Date

April 1, 2004

Primary Completion Date

October 1, 2013

Completion Date

September 1, 2015

Last Updated

October 14, 2015

Enrollment

ACTUAL participants

Conditions

Pancreatic Cancer

Interventions

Blood draw

PROCEDURE

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

RECRUITINGPHASE1/PHASE2

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 14, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Ghrelin Levels in Pancreatic Cancer Patients

Inclusion Criteria

Exclusion Criteria

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients